FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971888428> ?p ?o ?g. }

• W2971888428 endingPage "e21509" @default.
• W2971888428 startingPage "e21509" @default.
• W2971888428 abstract "e21509 Background: Participation of children with advanced solid cancers in phase I trials raises ethical and logistic dilemmas. Life-expectancy beyond 8-12 weeks is a common inclusion criterion, but it can be difficult to gauge. This multicentric European study assessed the mortality and survival rates in pediatric phase I trials. Methods: Retrospective study of patients aged < 18 years with solid tumors enrolled in phase I trials in ITCC centres between 2015-2017. Outcome variables were described and prognostic factors analysed. Results: 256 patients across 12 centres in 5 countries were eligible. Median age 11.8 years (range, 0.5-17.9). Female:Male ratio 1:1.9. Tumor location: central nervous system (CNS) 66% vs extra-CNS 34%. Main diagnoses: 22% soft tissue sarcomas, 13% high grade gliomas, 11% osteosarcomas. Most frequent therapy: single targeted agent (63%). Ten cases (4%) were not evaluable for response and 128 (50%) had progressive disease at first evaluation. Best responses were complete in 12 cases (5%), partial in 29 (11%) and stable disease in 77 (30%). Median follow-up 7 months (range, 0.5-42.4). Median Time On Study (TOS) 2.1 months (range, 0.2-38.1). The 30 and 90-day mortality on trial were 3% (8/256) and 21% (54/256), respectively. The 90-day survival (95%CI) for patients with CNS vs extra-CNS tumors was 88% (78-93) vs 76% (68-82), respectively. One-year Overall Survival (95%CI) for the whole sample was 40% (33-46). No toxic deaths on trial were reported. Twenty-five cases (10%) survived ≥365 days on trial. Median TOS 21.5 months (range, 12.3-38.1). Compared to patients who died within 365 days from Cycle1-Day1, those on trial ≥365 days had lower rates of metastatic disease (74% vs 28%, respectively, p < 0.001), higher objective response rates (13% vs 44%, respectively, p < 0.001) and higher disease stabilization (27% vs 56%, respectively, p < 0.001). Conclusions: Currently few patients die within the first cycle of treatment. However a fifth of all patients died within 3 months from trial initiation. Patients with CNS tumors have comparable survival rates to those with extra-CNS and should not be excluded from phase I trials solely because of their diagnosis. The survival rates beyond one year remain modest." @default.
• W2971888428 created "2019-09-12" @default.
• W2971888428 creator A5022270805 @default.
• W2971888428 creator A5024238674 @default.
• W2971888428 creator A5027415526 @default.
• W2971888428 creator A5031481733 @default.
• W2971888428 creator A5042196764 @default.
• W2971888428 creator A5044913583 @default.
• W2971888428 creator A5046361130 @default.
• W2971888428 creator A5047552026 @default.
• W2971888428 creator A5049484018 @default.
• W2971888428 creator A5051922909 @default.
• W2971888428 creator A5052706160 @default.
• W2971888428 creator A5052857128 @default.
• W2971888428 creator A5062226051 @default.
• W2971888428 creator A5067202962 @default.
• W2971888428 creator A5073707704 @default.
• W2971888428 creator A5074227857 @default.
• W2971888428 creator A5078018486 @default.
• W2971888428 creator A5078983265 @default.
• W2971888428 creator A5080273579 @default.
• W2971888428 creator A5085820190 @default.
• W2971888428 date "2019-05-20" @default.
• W2971888428 modified "2023-10-16" @default.
• W2971888428 title "Mortality and survival rates in children and adolescents enrolled in early phase trials with a dose-finding/dose-confirmation component: An innovative therapies for children with cancer (ITCC) study." @default.
• W2971888428 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e21509" @default.
• W2971888428 hasPublicationYear "2019" @default.
• W2971888428 type Work @default.
• W2971888428 sameAs 2971888428 @default.
• W2971888428 citedByCount "1" @default.
• W2971888428 countsByYear W29718884282022 @default.
• W2971888428 crossrefType "journal-article" @default.
• W2971888428 hasAuthorship W2971888428A5022270805 @default.
• W2971888428 hasAuthorship W2971888428A5024238674 @default.
• W2971888428 hasAuthorship W2971888428A5027415526 @default.
• W2971888428 hasAuthorship W2971888428A5031481733 @default.
• W2971888428 hasAuthorship W2971888428A5042196764 @default.
• W2971888428 hasAuthorship W2971888428A5044913583 @default.
• W2971888428 hasAuthorship W2971888428A5046361130 @default.
• W2971888428 hasAuthorship W2971888428A5047552026 @default.
• W2971888428 hasAuthorship W2971888428A5049484018 @default.
• W2971888428 hasAuthorship W2971888428A5051922909 @default.
• W2971888428 hasAuthorship W2971888428A5052706160 @default.
• W2971888428 hasAuthorship W2971888428A5052857128 @default.
• W2971888428 hasAuthorship W2971888428A5062226051 @default.
• W2971888428 hasAuthorship W2971888428A5067202962 @default.
• W2971888428 hasAuthorship W2971888428A5073707704 @default.
• W2971888428 hasAuthorship W2971888428A5074227857 @default.
• W2971888428 hasAuthorship W2971888428A5078018486 @default.
• W2971888428 hasAuthorship W2971888428A5078983265 @default.
• W2971888428 hasAuthorship W2971888428A5080273579 @default.
• W2971888428 hasAuthorship W2971888428A5085820190 @default.
• W2971888428 hasConcept C121608353 @default.
• W2971888428 hasConcept C126322002 @default.
• W2971888428 hasConcept C133925201 @default.
• W2971888428 hasConcept C141071460 @default.
• W2971888428 hasConcept C167135981 @default.
• W2971888428 hasConcept C187212893 @default.
• W2971888428 hasConcept C2908647359 @default.
• W2971888428 hasConcept C535046627 @default.
• W2971888428 hasConcept C71924100 @default.
• W2971888428 hasConcept C99454951 @default.
• W2971888428 hasConceptScore W2971888428C121608353 @default.
• W2971888428 hasConceptScore W2971888428C126322002 @default.
• W2971888428 hasConceptScore W2971888428C133925201 @default.
• W2971888428 hasConceptScore W2971888428C141071460 @default.
• W2971888428 hasConceptScore W2971888428C167135981 @default.
• W2971888428 hasConceptScore W2971888428C187212893 @default.
• W2971888428 hasConceptScore W2971888428C2908647359 @default.
• W2971888428 hasConceptScore W2971888428C535046627 @default.
• W2971888428 hasConceptScore W2971888428C71924100 @default.
• W2971888428 hasConceptScore W2971888428C99454951 @default.
• W2971888428 hasIssue "15_suppl" @default.
• W2971888428 hasLocation W29718884281 @default.
• W2971888428 hasOpenAccess W2971888428 @default.
• W2971888428 hasPrimaryLocation W29718884281 @default.
• W2971888428 hasRelatedWork W1586374228 @default.
• W2971888428 hasRelatedWork W2003938723 @default.
• W2971888428 hasRelatedWork W2045240138 @default.
• W2971888428 hasRelatedWork W2047967234 @default.
• W2971888428 hasRelatedWork W2118496982 @default.
• W2971888428 hasRelatedWork W2364998975 @default.
• W2971888428 hasRelatedWork W2369162477 @default.
• W2971888428 hasRelatedWork W2439875401 @default.
• W2971888428 hasRelatedWork W4238867864 @default.
• W2971888428 hasRelatedWork W2525756941 @default.
• W2971888428 hasVolume "37" @default.
• W2971888428 isParatext "false" @default.
• W2971888428 isRetracted "false" @default.
• W2971888428 magId "2971888428" @default.
• W2971888428 workType "article" @default.